Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Epidemiology and Surveillance

Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States

Rodrigo E. Mendes, Helio S. Sader, Robert K. Flamm, David J. Farrell, Ronald N. Jones
Rodrigo E. Mendes
JMI Laboratories, North Liberty, Iowa, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helio S. Sader
JMI Laboratories, North Liberty, Iowa, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert K. Flamm
JMI Laboratories, North Liberty, Iowa, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Farrell
JMI Laboratories, North Liberty, Iowa, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald N. Jones
JMI Laboratories, North Liberty, Iowa, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.04616-14
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • TABLE 1

    Antimicrobial activity and MIC distribution for telavancin against a contemporary (2011 to 2013) U.S. collection of S. aureus clinical isolates using a recently approved and revised susceptibility testing method

    S. aureus categorya (no. of isolates tested)MIC (μg/ml)No. (cumulative %) of isolates inhibited by telavancin at indicated MIC (μg/ml)b
    50%90%≤0.0150.030.060.12
    All (9,610)0.030.06364 (3.8)6,210 (68.4)3,012 (99.8)24 (100.0)
        MSSA (4,959)0.030.06242 (4.9)3,272 (70.9)1,437 (99.8)8 (100.0)
        MRSA (4,651)0.030.06122 (2.6)2,938 (65.8)1,575 (99.7)16 (100.0)
            Vancomycin MIC, ≤1 μg/ml (4,561)0.030.06119 (2.6)2,930 (66.8)1,502 (99.8)10 (100.0)
            Vancomycin MIC, 2–4 μg/ml (90)0.060.063 (3.3)8 (12.2)73 (93.3)6 (100.0)
            Daptomycin MIC, ≤0.5 μg/ml (4,607)0.030.06122 (2.6)2,928 (66.2)1,545 (99.7)12 (100.0)
            Daptomycin MIC, 1–2 μg/ml (43)0.060.060 (0.0)9 (20.9)30 (90.7)4 (100.0)
            MDR (1,371)0.030.0637 (2.7)749 (57.3)574 (99.2)11 (100.0)
            Non-MDR (3,280)0.030.0685 (2.6)2,189 (69.3)1,001 (99.8)5 (100.0)
    • ↵a MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; MDR, multidrug resistant.

    • ↵b Data representing modal MICs are shown in bold.

  • TABLE 2

    Antimicrobial activity of telavancin and comparator agents tested against a contemporary (2011 to 2013) U.S. collection of clinical isolates using a recently approved and revised susceptibility testing method

    Organism categorya (no. tested) and antimicrobial agentMIC (μg/ml)% susceptible/% intermediate/% resistantb
    50%90%FDACLSIEUCAST
    MSSA (4,959)
        Telavancin0.030.06100.0/-c/--/-/--/-/-
        Vancomycin11100.0/0.0/0.0100.0/0.0/0.0
        Daptomycin0.250.5>99.9/-/->99.9/0.0/<0.1
        Linezolid11>99.9/0.0/<0.1>99.9/0.0/<0.1
        Levofloxacin0.25488.8/0.9/10.388.8/0.9/10.3
        Erythromycin0.25>1665.6/3.7/30.766.0/1.3/32.7
        Clindamycin≤0.25≤0.2595.2/0.1/4.794.8/0.4/4.8
        Gentamicin≤1≤199.2/0.2/0.699.0/0.0/1.0
        Tetracycline≤0.25≤0.2596.2/0.7/3.195.3/0.2/4.5
        Trimethoprim-sulfamethoxazole≤0.5≤0.599.5/0.0/0.599.5/0.1/0.4
    MRSA (4,651)
        Telavancin0.030.06100.0/-/--/-/-100.0/-/-
        Vancomycin11>99.9/<0.1/0.0>99.9/0.0/<0.1
        Daptomycin0.250.5>99.9/-/->99.9/0.0/<0.1
        Linezolid1199.9/0.0/0.199.9/0.0/0.1
        Levofloxacin4>431.3/2.2/66.531.3/2.2/66.5
        Erythromycin>16>1610.4/1.9/87.710.6/0.5/88.9
        Clindamycin≤0.25>270.5/0.1/29.470.2/0.3/29.5
        Gentamicin≤1≤196.8/0.1/3.196.5/0.0/3.5
        Tetracycline≤0.25194.9/0.4/4.792.6/2.0/5.4
        Trimethoprim-sulfamethoxazole≤0.5≤0.597.8/0.0/2.297.8/0.2/2.0
    MRSA with vancomycin MIC 2–4 μg/ml (4,651)
        Telavancin0.060.06100.0/-/--/-/-100.0/-/-
        Vancomycin2298.9/1.1/0.098.9/0.0/1.1
        Daptomycin0.5197.8/-/-97.8/0.0/2.2
        Linezolid1298.9/0.0/1.198.9/0.0/1.1
        Levofloxacin>4>414.4/0.0/85.614.4/0.0/85.6
        Erythromycin>16>165.6/1.1/93.35.6/1.1/93.3
        Clindamycin>2>236.7/0.0/63.336.7/0.0/63.3
        Gentamicin≤1291.1/0.0/8.988.9/0.0/11.1
        Tetracycline≤0.25295.6/1.1/3.388.9/6.7/4.4
        Trimethoprim-sulfamethoxazole≤0.5≤0.597.8/0.0/2.297.8/1.1/1.1
    MDR MRSA (1,371)
        Telavancin0.030.06100.0/-/--/-/-100.0/-/-
        Vancomycin1199.9/0.1/0.099.9/0.0/0.1
        Daptomycin0.250.599.9/-/-99.9/0.0/0.1
        Linezolid1199.7/0.0/0.399.7/0.0/0.3
        Levofloxacin>4>40.9/0.3/98.80.9/0.3/98.8
        Erythromycin>16>160.5/0.4/99.10.5/0.1/99.4
        Clindamycin>2>26.3/0.0/93.76.3/0.0/93.7
        Gentamicin≤1490.2/0.2/9.689.9/0.0/10.1
        Tetracycline≤0.25>888.6/0.2/11.282.4/6.1/11.5
        Trimethoprim-sulfamethoxazole≤0.5≤0.593.9/0.0/6.193.9/0.7/5.4
    • ↵a MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; MDR, multidrug resistant.

    • ↵b Telavancin breakpoint criteria for S. aureus according to the labeling supplement for the product (Vibativ) and EUCAST (MRSA only) at ≤0.12 μg/ml for susceptibility.

    • ↵c -, breakpoint not available.

PreviousNext
Back to top
Download PDF
Citation Tools
Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States
Rodrigo E. Mendes, Helio S. Sader, Robert K. Flamm, David J. Farrell, Ronald N. Jones
Antimicrobial Agents and Chemotherapy Feb 2015, 59 (3) 1811-1814; DOI: 10.1128/AAC.04616-14

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States
Rodrigo E. Mendes, Helio S. Sader, Robert K. Flamm, David J. Farrell, Ronald N. Jones
Antimicrobial Agents and Chemotherapy Feb 2015, 59 (3) 1811-1814; DOI: 10.1128/AAC.04616-14
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596